摘要
目的探讨高血压社区规范化管理中5大类常用抗高血压药物的成本-效果分析,为临床合理选择降压药提供依据。方法随机抽取滨海新区-高血压社区规范化管理下的高血压人群作为调查对象,共选取符合5大类常用抗高血压药物的成本-效果分析要求的7014例患者。根据性别、年龄以及危险分层等基于样本最大化原则进行匹配,以此针对利尿剂、β受体阻滞剂、钙通道阻滞剂、血管紧张素转换酶抑制剂、血管紧张素2受体抑制剂各自治疗进行成本对照分析和疗效对照分析。结果利尿剂、β受体阻滞剂、钙通道阻滞剂、血管紧张素转换酶抑制剂、血管紧张素2受体抑制的成本-效果显示,血管紧张素2受体抑制剂以及利尿剂成本-效果较优(P<0.05)。结论血管紧张素转换酶抑制剂以及利尿剂综合成本低,治疗效果较佳,值得临床重视。
Objective To explore the cost-effectiveness analysis of five types of commonly used antihypertensive drugs in the standardized management of hypertensive communities. Methods The hypertensive population in the Binhai New Area-hypertension community standardized management was randomly selected as the object of investigation, a total of 7014 patients who met the cost effectiveness analysis requirements of 5 major antihypertensive drugs were selected. The matching was based on the principle of sample maximization according to gender, age, and risk stratification. Cost-control analysis and efficacy-control analysis were performed for diuretics, beta-blockers, calcium channel blockers, angiotensinconverting enzyme inhibitors, and angiotensin-2 receptor inhibitors. Results Cost-effectiveness of diuretics, beta-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin 2 receptor inhibition, cost of angiotensin 2 receptor inhibition and diuretics-Excellent results（P〈 0.05）. Conclusion The comprehensive cost of angiotensin-converting enzyme inhibitors and diuretics is low and the treatment effect is better. It is worthy of clinical attention.
作者
周航
刘亮
裴征
李鹿鹿
梁景亮
薛亮
ZHOU Hang;LIU Liang;PEI Zheng;LI Lu-lu;LIANG Jing-liang;XUE Liang(Tanggu Street Xingang Community Health Service Center of Binhai New District,Tianjin 300456;Tianjin Fifth Central Hospital,Tianjin 300450;Becang Town Community Health Service Center of Beichen District,Tianjin 300400;Tanggu Street Jiefang Road Community Health Service Center of Binhai New District,Tianjin 300451;Tianjin Yongjiu Hospital,Tianjin 300451)
出处
《智慧健康》
2018年第23期47-49,共3页
Smart Healthcare
关键词
高血压
社区规范化管理
抗高血压药物
成本-效果
Hypertension
Community standardized management
Antihypertensive drugs
Cost-effectiveness
